Pentraxin 3: A novel and independent prognostic marker in ischemic stroke

Wi Sun Ryu, Chi Kyung Kim, Beom Joon Kim, Chulho Kim, Seung Hoon Lee, Byung Woo Yoon

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: Pentraxin 3 (PTX3) is one of the pattern-recognition receptors related to the initial step of the immune response with C-reactive protein, but the physiologic and pathologic functions are not fully understood. The purpose of the current study was to determine the impact of PTX3 levels on mortality after ischemic stroke. Methods: We consecutively enrolled 376 patients who had ischemic stroke between September 2004 and September 2006. The patients were divided into tertiles according to PTX3 levels. Cox regression analysis was used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of the PTX3 tertiles for all-cause mortality with adjustment for traditional risk factors and laboratory variables, including C-reactive protein. Results: During the follow-up, 19.4% of the patients were deceased. The median PTX3 levels were higher in the deceased patients (18.0 vs. 6.4. ng/mL, p<0.001). Based on Cox regression analysis, compared with the first tertile of PTX3, the adjusted HRs of the second and third tertiles for all-cause mortality were 1.24 (95% CI, 0.52-2.98) and 2.64 (95% CI, 1.19-5.85), respectively. When the log-transformed levels of PTX3 were incorporated as continuous variables, higher levels of PTX3 were also associated with an increased mortality (increase per log unit; HR, 1.60; 95% CI, 1.19-2.16). Conclusions: We showed that higher levels of PTX3 are independently associated with increased mortality after ischemic stroke. Our results suggest that PTX3 may be used as a new powerful prognostic biomarker in patients with ischemic stroke.

Original languageEnglish
Pages (from-to)581-586
Number of pages6
JournalAtherosclerosis
Volume220
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1
Externally publishedYes

Fingerprint

Stroke
Mortality
Confidence Intervals
C-Reactive Protein
Regression Analysis
PTX3 protein
Pattern Recognition Receptors
Biomarkers

Keywords

  • Ischemic stroke
  • Mortality
  • Pentraxin 3

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pentraxin 3 : A novel and independent prognostic marker in ischemic stroke. / Ryu, Wi Sun; Kim, Chi Kyung; Kim, Beom Joon; Kim, Chulho; Lee, Seung Hoon; Yoon, Byung Woo.

In: Atherosclerosis, Vol. 220, No. 2, 01.02.2012, p. 581-586.

Research output: Contribution to journalArticle

Ryu, Wi Sun ; Kim, Chi Kyung ; Kim, Beom Joon ; Kim, Chulho ; Lee, Seung Hoon ; Yoon, Byung Woo. / Pentraxin 3 : A novel and independent prognostic marker in ischemic stroke. In: Atherosclerosis. 2012 ; Vol. 220, No. 2. pp. 581-586.
@article{f0a6c23bda8346068df38998bd064401,
title = "Pentraxin 3: A novel and independent prognostic marker in ischemic stroke",
abstract = "Objective: Pentraxin 3 (PTX3) is one of the pattern-recognition receptors related to the initial step of the immune response with C-reactive protein, but the physiologic and pathologic functions are not fully understood. The purpose of the current study was to determine the impact of PTX3 levels on mortality after ischemic stroke. Methods: We consecutively enrolled 376 patients who had ischemic stroke between September 2004 and September 2006. The patients were divided into tertiles according to PTX3 levels. Cox regression analysis was used to determine hazard ratios (HRs) and 95{\%} confidence intervals (CIs) of the PTX3 tertiles for all-cause mortality with adjustment for traditional risk factors and laboratory variables, including C-reactive protein. Results: During the follow-up, 19.4{\%} of the patients were deceased. The median PTX3 levels were higher in the deceased patients (18.0 vs. 6.4. ng/mL, p<0.001). Based on Cox regression analysis, compared with the first tertile of PTX3, the adjusted HRs of the second and third tertiles for all-cause mortality were 1.24 (95{\%} CI, 0.52-2.98) and 2.64 (95{\%} CI, 1.19-5.85), respectively. When the log-transformed levels of PTX3 were incorporated as continuous variables, higher levels of PTX3 were also associated with an increased mortality (increase per log unit; HR, 1.60; 95{\%} CI, 1.19-2.16). Conclusions: We showed that higher levels of PTX3 are independently associated with increased mortality after ischemic stroke. Our results suggest that PTX3 may be used as a new powerful prognostic biomarker in patients with ischemic stroke.",
keywords = "Ischemic stroke, Mortality, Pentraxin 3",
author = "Ryu, {Wi Sun} and Kim, {Chi Kyung} and Kim, {Beom Joon} and Chulho Kim and Lee, {Seung Hoon} and Yoon, {Byung Woo}",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.atherosclerosis.2011.11.036",
language = "English",
volume = "220",
pages = "581--586",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Pentraxin 3

T2 - A novel and independent prognostic marker in ischemic stroke

AU - Ryu, Wi Sun

AU - Kim, Chi Kyung

AU - Kim, Beom Joon

AU - Kim, Chulho

AU - Lee, Seung Hoon

AU - Yoon, Byung Woo

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Objective: Pentraxin 3 (PTX3) is one of the pattern-recognition receptors related to the initial step of the immune response with C-reactive protein, but the physiologic and pathologic functions are not fully understood. The purpose of the current study was to determine the impact of PTX3 levels on mortality after ischemic stroke. Methods: We consecutively enrolled 376 patients who had ischemic stroke between September 2004 and September 2006. The patients were divided into tertiles according to PTX3 levels. Cox regression analysis was used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of the PTX3 tertiles for all-cause mortality with adjustment for traditional risk factors and laboratory variables, including C-reactive protein. Results: During the follow-up, 19.4% of the patients were deceased. The median PTX3 levels were higher in the deceased patients (18.0 vs. 6.4. ng/mL, p<0.001). Based on Cox regression analysis, compared with the first tertile of PTX3, the adjusted HRs of the second and third tertiles for all-cause mortality were 1.24 (95% CI, 0.52-2.98) and 2.64 (95% CI, 1.19-5.85), respectively. When the log-transformed levels of PTX3 were incorporated as continuous variables, higher levels of PTX3 were also associated with an increased mortality (increase per log unit; HR, 1.60; 95% CI, 1.19-2.16). Conclusions: We showed that higher levels of PTX3 are independently associated with increased mortality after ischemic stroke. Our results suggest that PTX3 may be used as a new powerful prognostic biomarker in patients with ischemic stroke.

AB - Objective: Pentraxin 3 (PTX3) is one of the pattern-recognition receptors related to the initial step of the immune response with C-reactive protein, but the physiologic and pathologic functions are not fully understood. The purpose of the current study was to determine the impact of PTX3 levels on mortality after ischemic stroke. Methods: We consecutively enrolled 376 patients who had ischemic stroke between September 2004 and September 2006. The patients were divided into tertiles according to PTX3 levels. Cox regression analysis was used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of the PTX3 tertiles for all-cause mortality with adjustment for traditional risk factors and laboratory variables, including C-reactive protein. Results: During the follow-up, 19.4% of the patients were deceased. The median PTX3 levels were higher in the deceased patients (18.0 vs. 6.4. ng/mL, p<0.001). Based on Cox regression analysis, compared with the first tertile of PTX3, the adjusted HRs of the second and third tertiles for all-cause mortality were 1.24 (95% CI, 0.52-2.98) and 2.64 (95% CI, 1.19-5.85), respectively. When the log-transformed levels of PTX3 were incorporated as continuous variables, higher levels of PTX3 were also associated with an increased mortality (increase per log unit; HR, 1.60; 95% CI, 1.19-2.16). Conclusions: We showed that higher levels of PTX3 are independently associated with increased mortality after ischemic stroke. Our results suggest that PTX3 may be used as a new powerful prognostic biomarker in patients with ischemic stroke.

KW - Ischemic stroke

KW - Mortality

KW - Pentraxin 3

UR - http://www.scopus.com/inward/record.url?scp=84855915960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855915960&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.11.036

DO - 10.1016/j.atherosclerosis.2011.11.036

M3 - Article

C2 - 22178425

AN - SCOPUS:84855915960

VL - 220

SP - 581

EP - 586

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -